Haiwen & Partners acts for both PRC biotech companies and large foreign financial services investors, assisting with financing work in the healthcare and life sciences space. Practice head Tina Wu is also highly experienced in clinical research, product development and regulatory compliance matters. Key names on the transactional and investment funds side include Hao Bian and Wenzhen Dai.
Legal 500 Editorial commentary
Key clients
- China International Capital Corporation Hong Kong Securities Limited
- Morgan Stanley Asia Limited
- Warburg Pincus
- Beijing Strong Biotechnologies, Inc.
- CICC
- Goldman Sachs
- BNP Paribas Securities (Asia) Limited
- Ping An Healthcare and Technology Company Limited
- Citigroup Global Markets Asia Limited
- Clarity Medical Group Holding Limited
- BMC Medical Co. Ltd.
- Lepuxintai Medical Technology (Shanghai) Co., Ltd.
- Hangzhou Calibra Diagnostics Co., Ltd.
- Demant A/S
- JJET
- HEALTH GUARD BIOMED
Work highlights
- Advised Lepu Biopharma Co., Ltd. on issuing shares and listing on the main board of the Hong Kong Stock Exchange.
- Assisted ByteDance with acquiring 100% equity of Amcare.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Tina Wu